Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Trexquant Investment LP

Key Points

• Trexquant Investment LP increased its stake in Catalyst Pharmaceuticals by 7.4% in the first quarter, owning approximately 0.18% of the company valued at $5.38 million.
• Director David S. Tierney and CEO Richard J. Daly sold shares of Catalyst Pharmaceuticals, reducing their ownership by 6.41% and 9.20% respectively, accumulating a total of $3.43 million in sales.
• Analysts have varied ratings on CPRX, with two assigning a Strong Buy rating, while Wall Street Zen and Zacks have downgraded their ratings to Hold.

Trexquant Investment LP lifted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 7.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 221,820 shares of the biopharmaceutical company's stock after buying an additional 15,331 shares during the period. Trexquant Investment LP owned approximately 0.18% of Catalyst Pharmaceuticals worth $5,379,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in CPRX. Hsbc Holdings PLC boosted its position in shares of Catalyst Pharmaceuticals by 64.7% during the fourth quarter. Hsbc Holdings PLC now owns 36,337 shares of the biopharmaceutical company's stock worth $764,000 after buying an additional 14,269 shares during the period. Susquehanna International Group LLP boosted its position in shares of Catalyst Pharmaceuticals by 2.4% during the fourth quarter. Susquehanna International Group LLP now owns 99,213 shares of the biopharmaceutical company's stock worth $2,071,000 after buying an additional 2,291 shares during the period. Voya Investment Management LLC boosted its position in shares of Catalyst Pharmaceuticals by 24.9% during the fourth quarter. Voya Investment Management LLC now owns 52,416 shares of the biopharmaceutical company's stock worth $1,094,000 after buying an additional 10,465 shares during the period. Tudor Investment Corp ET AL acquired a new position in shares of Catalyst Pharmaceuticals during the fourth quarter worth approximately $1,243,000. Finally, Northern Trust Corp boosted its position in shares of Catalyst Pharmaceuticals by 8.7% during the fourth quarter. Northern Trust Corp now owns 1,503,566 shares of the biopharmaceutical company's stock worth $31,379,000 after buying an additional 119,766 shares during the period. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 1,600 shares of the company's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total value of $42,272.00. Following the transaction, the insider owned 41,081 shares of the company's stock, valued at approximately $1,085,360.02. This represents a 3.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Richard J. Daly sold 22,970 shares of the stock in a transaction on Tuesday, August 26th. The shares were sold at an average price of $20.62, for a total value of $473,641.40. Following the sale, the chief executive officer owned 226,794 shares of the company's stock, valued at $4,676,492.28. This trade represents a 9.20% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 167,894 shares of company stock valued at $3,434,690. 10.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on CPRX shares. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Wall Street Zen downgraded Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Zacks Research downgraded Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $33.20.

Catalyst Pharmaceuticals Stock Up 0.1%

CPRX traded up $0.01 during trading on Thursday, reaching $19.80. The stock had a trading volume of 2,242,189 shares, compared to its average volume of 1,325,839. The firm has a market capitalization of $2.42 billion, a price-to-earnings ratio of 12.00, a price-to-earnings-growth ratio of 0.84 and a beta of 0.85. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.00 and a 1-year high of $26.58. The stock has a 50 day moving average of $20.93 and a two-hundred day moving average of $22.46.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.